SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
Recruiting now
Conditions studied: Ischemic Stroke, Embolic Stroke of Undetermined Source, Patent Foramen Ovale (PFO), Elderly
In brief
Patent foramen ovale (PFO) is an important mechanism of embolic stroke of undetermined source (ESUS). Current guidelines recommend PFO closure for high-risk PFO in patients younger than 60 years, and a recent retrospective cohort study from Taichung Veterans General Hospital has shown that closure is effective and safe in older adults; however, the optimal treatment strategy for those \>60 years and direct head-to-head comparisons of PFO closure versus direct oral anticoagulants (DOACs) remain insufficient. Robust evidence from a multicenter study combining prospective and retrospective cohorts is warranted. The SENIOR study is a multicenter observational cohort registry with a combined retrospective and prospective design. The prospective period is from September 15, 2025 to December 31, 2031, and the retrospective period covers January 1, 2013 to September 1, 2025; target sample sizes are 400 (prospective) and 500 (retrospective). We will enroll adults with ESUS and PFO; the prospective arm will focus on patients aged \>60 years with PFO related stroke. Treatments will be assigned as PFO closure, standard-dose DOAC, or antiplatelet agents (if DOAC intolerance) by local principal investigator. The primary outcome is recurrent ischemic stroke or transient ischemic attack. Secondary outcomes include 6-month functional outcome, all stroke, and serial comparison of atrial cardiopathy changes. Safety endpoints include peri-procedural adverse events (including newly-onset atrial fibrillation), hemorrhagic stroke, and all caused mortality. Clinical presentation, imaging, cardiac testing, biomarker, and genetic data will be collected for stratified and multivariable analyses.
Key facts
- Study ID
- NCT07479147
- Run by
- Taichung Veterans General Hospital
- People needed
- 400
- Starts
- 2025-12-16
- Expected to finish
- 2031-12-31
- Last updated by the study team
- 2026-03-23
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient or his/her legal representative signs a written informed consent
- Participants who have diagnosed as PFO related stroke
- For patient aged 18-59: patient with high risk PFO feature or RoPE score ≥ 7
- For patient aged 60-90: patient with high risk PFO feature or RoPE score ≥ 4, must include cortical infarct
You may not qualify if…
- Follow-up less than 6 months
- Extracardiac right-to-left shunt
- Known stroke mechanism was diagnosed
Where it is running
- Taichung Veterans General Hospital — Taichung, Taiwan (enrolling)
- National Taiwan University Hospital — Taipei, Taiwan (enrolling)
- Taipei Veterans General Hospital — Taipei, Taiwan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.